Replay Now

Pre-Recorded Webinars 2011

• Speaker Bio

  Kamala Tyagarajan Ph.D. Dr. Kamala Tyagarajan is a Senior R&D Manager at EMD Millipore where she leads a team responsible for applications development on multiple guava® cytometric platforms. Kamala has extensive experience with fluorescent-based probes and technologies. She was previously Director of Applications Development at Guava Technologies, and was involved with the development of cell and blood-based cytometric solutions for several years. Prior, Kamala was a Staff Scientist at Lynx Therapeutics working on novel fluorescent-based technologies for proteomics. Kamala performed her doctoral and post-doctoral studies at the University of California, Berkeley working on protein post-translational modifications and proteomics.

• Webinar Abstract
  Mitochondria are critical cellular organelles that are responsible for cellular energetics, apoptosis regulation and generation of oxidative stress. Mitochondrial impairment has been implicated in several diseases and is being increasingly studied in the drug discovery screening process. In this webinar, we demonstrate the power and simplicity of EMD Millipore’s microcapillary cytometry solutions to rapidly screen cellular samples and distinguish compound effects on key cell and mitochondrial health markers. Simultaneous, multiparametric interrogation of mitochondrial and cell health markers provides valuable insights into understanding mode of action of compounds in screening studies.

• Speaker Bio

  Paul Joseph Paul Joseph is a field application scientist for EMD Millipore. He did his undergraduate degree in Microbiology at the University of Massachusetts at Amherst. Prior to joining EMD Millipore, he worked for Genome Therapeutics Corporation generating DNA sequencing data of chromosome 10 for the Human Genome Project. As well as, the area of pharmacogenomics where he participated in the SNP analysis of several genes related to pain and inflammation. He completed his graduate degree in Infectious Disease, Microbiology and Molecular Virology at the University of Pittsburgh in a herpes virus lab studying the molecular mechanisms involved in the pathogenesis of Post Transplant Lymphoproliferative Disorder.

• Webinar Abstract
  Western blotting is a powerful and sensitive technique used to detect low amounts of proteins in complex samples, or to monitor protein expression and purification by protein blotting and immunodetection. Difficulties with this technique arise from poor protein transfer and antibody performance, both complicated and critical parts to the procedure, but completely optimizable with some key knowledge on membrane and antibody mechanics. We invite you to come and experience an opportunity to gain more technical insight on of the science and optimization of Western blotting.
  

• Speaker Bio

  	Joanna Riddoch-Contreras Ph.D. Dr. Joanna Riddoch-Contreras is a post-doctoral research scientist, working on Alzheimer’s disease Biomarkers at the Institute of Psychiatry since February 2009. Prior to joining Kings, Joanna was awarded a BSc in Neuroscience in 2003 from University College London (UCL) and then continued to complete a Ph.D. in Neuroscience at the Institute of Neurology, Queens Square in 2007. Joanna Riddoch-Contreras is currently funded by the Medical Research Council.
  	Abdul Hye, Ph.D. Dr. Abdul Hye is post-doctoral scientist in the Old Age Psychiatry Department at the Institute of Psychiatry. He did his undergraduate in Physiology and Pharmacology at the Nottingham Trent University. After graduation he worked for Unilever in their toxicology department for 18 months, using proteomics to identify markers of skin irritation using their patented 3D skin cell model. He completed his Ph.D. at the Institute of Psychiatry looking at blood based biomarkers for Alzheimer’s disease using various proteomic technologies. He is currently involved in developing an immunoassay for commercial and research use using the bead-based Luminex® platform.

• Webinar Abstract
  Considerable advances in our understanding of Alzheimer’s disease has revealed an increasing pressing need for etiological biomarkers. Markers of prediction, early diagnosis and progression have been identified in plasma. No single biomarker alone has sufficient power to be a diagnostic or a progression marker, therefore screening a combination of markers is necessary. We have selected a multiplexing approach using the Luminex® xMAP® bead-based platform to validate our biomarkers with the aim to achieve the highest specificity and sensitivity.

• Speaker Bio

  Takeshi Shimamura Ph.D. Dr. Takeshi Shimamura is an Assistant Professor at the Oncology Institute, Department of Molecular Pharmacology and Therapeutics, Loyola University, Chicago. He received his Ph.D. at Western Michigan University, where he studied roles of NF-κB in PDGF-BB mediated cellular transformation. He was previously an Instructor of Medicine at Dana-Farber Cancer Institute - Harvard Medical School, where his research focused on signal transduction of cancer and preclinical characterization of small molecule drugs for cancer. As a postdoctoral fellow at Dana-Farber, Dr. Shimamura contributed to the discovery of the therapeutic potential of Hsp90 inhibition in lung cancer and his findings on inhibitor interactions have now been translated into clinical trials. Dr. Shimamura joined the research faculty of the Oncology Institute at Loyola University of Chicago in late 2011. His primary research interest is in the area of signaling Pathways of NSCLC undergoing epithelial to mesenchymal transition (EMT) in NSCLC and Small-Cell Lung Cancer (SCLC).

• Webinar Abstract
  Western blotting and traditional multiplex signaling assays can reveal only relative changes in protein levels, requiring normalization for cross-pathway analysis. MILLIPLEX® MAP EpiQuant assays provide absolute quantitation of total and phosphorylated proteins, which enable direct comparison of signaling events in different pathways. Dr. Shimamura will demonstrate the power of the EpiQuant technology using the EpiQuant EGFR Signaling Pathway Panel to study the effects of kinase inhibitors that are in clinical development on EGFR-driven NSCLC cell lines.
  

• Speaker Bio

  Matthew Hsu Ph.D. Dr. Matthew H. Hsu,in his 8th year as R&D Director at EMD Millipore, currently leads the development team for advanced cellular technologies focusing on systems biology and single cell analysis. Matthew received his Ph.D. in Biochemistry from Baylor College of Medicine and completed post-doctoral training in Immunology at the Scripps Research Institute. He first led R&D efforts in mammalian expression systems and high throughput screening at Stratagene, then moved to Neurocrine Biosciences, Inc. to lead small molecule drug development. At EMD Millipore, Matthew helped launch hundreds of products including the industry’s first cell-based GPCR profiling and screening services, HCA assays for toxicology, and kits for stem cell characterization.

• Webinar Abstract
  Autophagy is an intracellular catabolic pathway implicated in diverse diseases including Alzheimer's disease, aging, cancers, and Crohn's disease. Current methods for studying autophagy such as immunoblotting and microscopy are very laborious and subjective, requiring manual cell counting or densitometry. Here we describe a novel flow cytometric assay using a monomeric GFP-LC3 autophagy reporter that enables the automated measurement and quantification of autophagy for screening inducers/inhibitors, monitoring cell health, protein degradation and identification of new pathway targets.